344 related articles for article (PubMed ID: 30904337)
1. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
[TBL] [Abstract][Full Text] [Related]
2. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
Broner EC; Tropé CG; Reich R; Davidson B
Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
[TBL] [Abstract][Full Text] [Related]
4. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.
Onallah H; Catane LJ; Tropé CG; Hetland Falkenthal TE; Reich R; Davidson B
Virchows Arch; 2018 Oct; 473(4):463-470. PubMed ID: 30032361
[TBL] [Abstract][Full Text] [Related]
5. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; Holth A; Dong HP
Virchows Arch; 2020 Nov; 477(5):677-685. PubMed ID: 32472195
[TBL] [Abstract][Full Text] [Related]
6. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its effect on biologic characteristics of colonic cancer stem cells].
Yan ZY; Sun XC
Zhonghua Bing Li Xue Za Zhi; 2018 Apr; 47(4):284-290. PubMed ID: 29690669
[No Abstract] [Full Text] [Related]
7. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.
Harel-Dassa K; Yedgar S; Tropé CG; Davidson B; Reich R
Hum Pathol; 2017 Apr; 62():115-121. PubMed ID: 28087476
[TBL] [Abstract][Full Text] [Related]
8. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression.
Fu TY; Hsieh IC; Cheng JT; Tsai MH; Hou YY; Lee JH; Liou HH; Huang SF; Chen HC; Yen LM; Tseng HH; Ger LP
J Oral Pathol Med; 2016 Feb; 45(2):89-95. PubMed ID: 26211876
[TBL] [Abstract][Full Text] [Related]
9. Relative Expression of OCT4, SOX2 and NANOG in Oral Squamous Cell Carcinoma Versus Adjacent Non- Tumor Tissue.
Baghai Naini F; Aminishakib P; Abdollahi A; Hodjat M; Mohammadpour H; Kardouni Khoozestani N
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1649-1654. PubMed ID: 31244283
[TBL] [Abstract][Full Text] [Related]
10. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
[TBL] [Abstract][Full Text] [Related]
11. Expression of SOX2, NANOG and OCT4 in a mouse model of lipopolysaccharide-induced acute uterine injury and intrauterine adhesions.
Xiao L; Song Y; Huang W; Yang S; Fu J; Feng X; Zhou M
Reprod Biol Endocrinol; 2017 Mar; 15(1):14. PubMed ID: 28253866
[TBL] [Abstract][Full Text] [Related]
12. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Cellular Transforming Activity of OCT4, NANOG, and SOX2 in Immortalized Astrocytes.
Seo S; Jeon HY; Kim H
DNA Cell Biol; 2017 Nov; 36(11):1000-1009. PubMed ID: 28933914
[TBL] [Abstract][Full Text] [Related]
14. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer.
You L; Guo X; Huang Y
Yonsei Med J; 2018 Jan; 59(1):35-42. PubMed ID: 29214774
[TBL] [Abstract][Full Text] [Related]
16. CHD7, Oct3/4, Sox2, and Nanog control FoxD3 expression during mouse neural crest-derived stem cell formation.
Fujita K; Ogawa R; Ito K
FEBS J; 2016 Oct; 283(20):3791-3806. PubMed ID: 27579714
[TBL] [Abstract][Full Text] [Related]
17. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
18. Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.
Belotte J; Fletcher NM; Alexis M; Morris RT; Munkarah AR; Diamond MP; Saed GM
Reprod Sci; 2015 Jan; 22(1):38-46. PubMed ID: 25038052
[TBL] [Abstract][Full Text] [Related]
19. Changes in the methylation status of the Oct3/4, Nanog, and Sox2 promoters in stem cells during regeneration of rat tracheal epithelium after injury.
Zhou Y; Song N; Li X; Han Y; Ren Z; Xu JX; Han YC; Li F; Jia X
Oncotarget; 2017 Jan; 8(2):2984-2994. PubMed ID: 27935870
[TBL] [Abstract][Full Text] [Related]
20. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma.
Habu N; Imanishi Y; Kameyama K; Shimoda M; Tokumaru Y; Sakamoto K; Fujii R; Shigetomi S; Otsuka K; Sato Y; Watanabe Y; Ozawa H; Tomita T; Fujii M; Ogawa K
BMC Cancer; 2015 Oct; 15():730. PubMed ID: 26483189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
